Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Entree Resources Ltd
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
August 6, 2026
Entrée Resources Announces Appointment Of Director
July 27, 2026
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
July 15, 2026
Entrée Resources Announces Details of Chief Executive Officer Transition
July 13, 2026
Entrée Resources Announces 2026 AGM Results and Election of New Director
June 18, 2026
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
June 2, 2026
Entrée Resources Announces First Quarter 2026 Results and Provides Corporate Update
May 30, 2026
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
May 22, 2026
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
May 21, 2026
Entrée Resources Announces Fiscal Year 2025 Results and Reviews Q4 Corporate Highlights
May 16, 2026
1
2
Next Page
→